Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

1035TiP - A phase I/Ib study of MPT-0118 as monotherapy and in combination with pembrolizumab in subjects with advanced or metastatic solid tumors

Date

16 Sep 2021

Session

ePoster Display

Topics

Cytotoxic Therapy;  Clinical Research

Tumour Site

Presenters

David Sommerhalder

Citation

Annals of Oncology (2021) 32 (suppl_5): S829-S866. 10.1016/annonc/annonc705

Authors

D. Sommerhalder1, E.A. Lim2, A. Pande3, P. Keller3

Author affiliations

  • 1 Clinical Research, NEXT Oncology, 78229 - San Antonio/US
  • 2 Oncology, Columbia University Herbert Irving Comprehensive Cancer Center, 10032 - New York/US
  • 3 R&d, Monopteros Therapeutics, 01966 - Rockport/US

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1035TiP

Background

MPT-0118 is an inhibitor of mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) protease developed by Monopteros Therapeutics for the treatment of solid tumors. Despite the transforming effects of immune checkpoint therapy (ICT), objective response rates are still low in solid tumors. In the tumor microenvironment (TME), regulatory T-cells (Treg) are unstable and can be reprogrammed to lose their immunosuppressive function and secrete interferon-γ, offering a strategy to sensitize unresponsive tumors to ICT. Blockade of MALT1 protease by MPT-0118 induces Treg reprogramming in the TME without affecting Treg in healthy tissue, which allows for cytotoxic T-lymphocyte-mediated tumor lysis and recruitment of new tumor-infiltrating lymphocytes. The increased inflammation caused by these effects then increases programmed death-ligand 1 expression allowing synergy between MPT-0118 and pembrolizumab.

Trial design

Monopteros Therapeutics is conducting a first-in-human, phase 1/1b open-label, multicenter, dose-escalation, safety, pharmacokinetics, and biomarker study of MPT-0118 as monotherapy and in combination with pembrolizumab in approximately 70 adults with advanced/metastatic refractory solid tumors. The study will be conducted in 3 parts: Part A: MPT-0118 monotherapy with 3+3 dose-escalation Part B: MPT-0118 in combination with standard dose of pembrolizumab with 3+3 dose-escalation Part C: Cohort expansion of MPT-0118 and pembrolizumab combination at the recommended phase 2 dose (RP2D) MPT-0118 will be administered orally twice daily to subjects in each part of the study, and pembrolizumab will be administered intravenously to subjects in Parts B, and C. Subjects will receive treatment in 3- or 4-week cycles and may continue on the study as long as they are tolerating treatment without disease progression. The primary objectives of Parts A and B are to determine the safety and tolerability, maximum tolerated dose, dose limiting toxicities, and RP2D of MPT-0118 as monotherapy and in combination. The primary objectives of Part C are to confirm safety in combination and to evaluate the preliminary anti-tumor activity.

Clinical trial identification

NCT04859777.

Editorial acknowledgement

Legal entity responsible for the study

Monopteros Therapeutics Inc.

Funding

Monopteros Therapeutics Inc.

Disclosure

E.A. Lim: Financial Interests, Stocks/Shares: Pfizer. A. Pande: Financial Interests, Personal, Advisory Role: Monopteros Therapeutics; Financial Interests, Member of the Board of Directors: Sio Gene Therapie; Financial Interests, Member of the Board of Directors: Karuna Therapeutics; Financial Interests, Member of the Board of Directors: Immunovant; Financial Interests, Member of the Board of Directors: Autifony Therapeutics; Financial Interests, Member of the Board of Directors: Perception Neurosciences; Financial Interests, Advisory Role: MAPS Public Benefit Corporation; Financial Interests, Advisory Role: MMS Holdings; Financial Interests, Advisory Role: Datavant; Financial Interests, Advisory Role: PureTech Health; Financial Interests, Advisory Role: Avanir Pharmaceuticals. P. Keller: Financial Interests, Personal, Full or part-time Employment: Monopteros Therapeutics; Financial Interests, Personal, Leadership Role: Divide and Conquer. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.